Regulation is not background noise. In European life sciences, it is part of the commercial model.
This section tracks the policy, access, compliance, and approval changes that shape adoption, timing, and strategic options.
AI in healthcare is often sold as a story of improved diagnostics, personalised therapies, and predictive medicine. But beneath that dream lies a fragile backbone: security. One breach, one exploited model, and reputations, finances, even lives are at stake. In Europe, this tension is amplified. The Artificial Intelligence Act entered into force on 1 August…
Think AI alone is transforming healthcare? Think again. The real game-changer could be quantum computing, particularly when paired with supercomputers. This isn’t future fiction anymore. It’s happening now. What’s New—and Why It Matters Combining quantum computing and supercomputers enables molecular simulations, like insulin dynamics involving tens of thousands of orbital. Classical systems simply could not…
Europe’s Quantum Moment Europe is not just a consumer of quantum technologies, it’s investing heavily to become a global leader. The Quantum Technologies Flagship commits €1 billion over 10 years to research and commercial pilots. Add Horizon Europe and EuroHPC’s hybrid supercomputers, and you get a uniquely European playbook: strong public co-funding, national champions, and…
The Threat Healthcare runs on trust — but its digital backbone is fragile. A sufficiently powerful quantum computer will run Shor’s algorithm, breaking RSA and elliptic curve cryptography. That means everything from EHRs to connected pacemakers is at risk. And the danger isn’t hypothetical. Adversaries are already engaging in “Harvest Now, Decrypt Later” (HNDL) — collecting encrypted medical…
Forget IPO hype. Europe’s MedTech scene is quietly reinventing exit strategies. The recent blockbuster OrganOx deal shows that patient-growth capital and global acquirers, not public markets, may set the real pace for scaling life-saving innovation. OrganOx’s $1.5B Exit: A MedTech Precedent in a Quiet Market Oxford-based OrganOx, a university spin‑out, has secured one of the…
Eight years of lawsuits. Zero damages paid. And now, a partnership. After nearly a decade of courtroom brawls, Veeva and IQVIA have finally ended their long-running legal dispute. On 18 August 2025, the rivals dismissed all claims with prejudice (read: permanently), and instead signed multi-year agreements to integrate their data and software platforms From Courtroom…
Stop calling Poland a nearshore Poland isn’t just shipping code for someone else’s roadmap. It’s producing digital health products used by tens of millions, and it’s hosting serious pharma/biotech tech operations—not just shared services. If you still think of it as a low‑cost back office, you’re reading a 2015 brochure. Poland healthtech at a glance…
For most European medtech scale-ups, the US isn’t just another market — it’s the market. A successful launch across the Atlantic can double or triple a company’s valuation. But now, that expansion plan comes with a new 15% question mark. On 5 August 2025, MedTech Europe warned that recent trade developments could see certain EU…
The EU wants to be the global leader in AI and in medical technology. Unfortunately, its own flagship regulations are on a collision course. Europe’s innovators are stuck in the middle. One year after the EU AI Act entered into force, the continent’s medtech trade body MedTech Europe is calling for a four-year delay in…
FAQ #11: What Does the Future Hold for Omnichannel Marketing in Healthcare? The future of omnichannel marketing in healthcare will be shaped by AI-driven personalization, integrated digital ecosystems, and evolving patient expectations that demand seamless, value-driven experiences across all touchpoints. Several key trends are converging to create unprecedented opportunities for customer engagement.1 AI and Generative Technologies Leading…